Skip to Main Content
Yale School of Medicine
YSM Home

INFORMATION FOR

Study Identifies High-Risk Mutation in Younger Appendiceal Cancer Patients

Yale researchers led by surgeon-scientist Kiran Turaga, MD, MBA, examined genomic differences between early- and late-onset appendiceal cancer and identified a high-risk PIK3CA mutation in younger patients, with important implications for prognosis and targeted therapy development.

PIK3CA Mutations Linked to Poor Survival in Early Appendiceal Cancer

Publication Title: PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma

Summary

Question
This study examined the genetic differences between early-onset appendiceal adenocarcinoma (EOAC), diagnosed in patients under 50 years old, and late-onset appendiceal adenocarcinoma (LOAC), diagnosed in patients 50 years or older. The researchers specifically investigated the prevalence of PIK3CA mutations and their association with survival outcomes in these groups.
Why it Matters
Appendiceal adenocarcinoma is a rare cancer with distinct features based on the age of onset. Understanding molecular differences between EOAC and LOAC can help identify specific genetic markers, such as PIK3CA mutations, that influence prognosis and treatment outcomes. These insights are important for tailoring therapies and improving survival rates, particularly as EOAC cases are increasing among younger populations.
Methods
The researchers conducted a retrospective analysis using genomic data from 200 patients with appendiceal adenocarcinoma. Patients were divided into EOAC (under 50 years old) and LOAC (50 years or older) groups based on age at surgery. Genetic profiles were analyzed using sequencing data from the Memorial Sloan Kettering MetTropism database and validated with the AACR GENIE database. Statistical models assessed mutation prevalence and survival associations.
Key Findings
PIK3CA mutations were significantly more common in EOAC than LOAC, occurring in 17.1% of EOAC cases compared to 7.7% of LOAC cases. These mutations were exclusively observed in patients with metastatic disease and were linked to worse overall survival. Patients with PIK3CA mutations had a lower 3-year survival probability (41%) compared to those without the mutation (72%).
Implications
The findings highlight PIK3CA mutation status as a critical prognostic marker in appendiceal adenocarcinoma. Incorporating molecular profiling into treatment planning could help identify high-risk patients and guide the development of targeted therapies, such as PI3K inhibitors, to improve outcomes, particularly for EOAC patients.
Next Steps
The authors suggest further research to explore the functional role of PIK3CA mutations in appendiceal tumor development and evaluate the clinical effectiveness of PI3K-targeted therapies in this cancer type. They also recommend expanding studies to include diverse populations and early-stage tumors to validate findings.
Funding Information
This research was supported by grants from the National Medical Research Council (NMRC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Yale University also provided funding and support for this research.

Full Citation

Gupta P, Gujarathi R, Qiao L, Godfrey E, Schultz K, Butensky S, Bader J, Sundar R, Cecchini M, Shergill A, Sheltzer J, Turaga K. PIK3CA Mutations in Early-Onset Appendiceal Adenocarcinoma. JCO Precision Oncology 2026, 10: e2500741. PMID: 41712872, DOI: 10.1200/po-25-00741.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.

Authors

  • Princy Gupta

    First Author
    School Building Streamline Icon: https://streamlinehq.comOther Institution

  • Kiran Turaga, MD, MPH

    Last Author
    Yale School of Medicine

    Professor of Surgery (Oncology)

    View Full Profile

Additional Yale School of Medicine Authors

Other Authors

  • Rushabh Gujarathi;
  • Lu Qiao;
  • Samuel D. Butensky;
  • Ardaman Shergill;
  • Jason M. Sheltzer

Research Themes

Keywords

Concepts